Literature DB >> 31501825

Impact of Statewide Telestroke Network on Acute Stroke Treatment in Hawai'i.

Hally M Chaffin1,2, Kazuma Nakagawa1,2, Matthew A Koenig1,2.   

Abstract

Hawai'i faces unique challenges in providing access to subspecialty care, particularly on the islands outside of O'ahu. Telemedicine allows remote treatment of patients with acute ischemic stroke by a neurologist with stroke expertise. The Hawai'i Telestroke Program was implemented in 2012 to connect hospitals with limited neurology coverage to a tertiary stroke center on O'ahu with 24/7 stroke neurology coverage. By 2017, seven hospitals were included in the program. The clinical data and revascularization therapy rate for all telestroke cases between January 2012 and July 2017 were analyzed. Annual telestroke consultations increased from 11 in 2012 to 203 in 2016. Among a total of 490 telestroke consultations, 318 patients (64.9%) were diagnosed with ischemic stroke while the remaining 172 patients had other diagnoses. Revascularization therapies, including intravenous tissue plasminogen activator and mechanical thrombectomy, were provided in 190 patients (38.8%). Using the discharge modified Rankin Scale, 141 (44.3%) patients were functionally independent at the time of hospital discharge, while 162 (50.9%) were disabled or dependent, and 15 (4.7%) died while in the hospital. Of the 490 telestroke consultations, 151 patients (30.8%) were transferred to the hub hospital while 69.2% of patients were able to remain in their local hospital. In summary, development of the Hawai'i Telestroke Program resulted in an increasing number of acute telestroke consultations and revascularization therapies at seven hospitals with limited neurological subspecialty coverage. Utilization of telemedicine in acute stroke treatment is feasible and may help address existing disparities of subspecialty care in Hawai'i.

Entities:  

Keywords:  acute ischemic stroke; functional outcomes; inter-hospital transfer; stroke mimics; telemedicine; tissue plasminogen activator

Mesh:

Year:  2019        PMID: 31501825      PMCID: PMC6731184     

Source DB:  PubMed          Journal:  Hawaii J Health Soc Welf        ISSN: 2641-5216


  28 in total

1.  Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia.

Authors:  O Y Chernyshev; S Martin-Schild; K C Albright; A Barreto; V Misra; I Acosta; J C Grotta; S I Savitz
Journal:  Neurology       Date:  2010-03-24       Impact factor: 9.910

2.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.

Authors:  Nils Wahlgren; Niaz Ahmed; Antoni Dávalos; Gary A Ford; Martin Grond; Werner Hacke; Michael G Hennerici; Markku Kaste; Sonja Kuelkens; Vincent Larrue; Kennedy R Lees; Risto O Roine; Lauri Soinne; Danilo Toni; Geert Vanhooren
Journal:  Lancet       Date:  2007-01-27       Impact factor: 79.321

3.  Remote supervision of IV-tPA for acute ischemic stroke by telemedicine or telephone before transfer to a regional stroke center is feasible and safe.

Authors:  Muhammad A Pervez; Gisele Silva; Shihab Masrur; Rebecca A Betensky; Karen L Furie; Renzo Hidalgo; Fabricio Lima; Eric S Rosenthal; Natalia Rost; Anand Viswanathan; Lee H Schwamm
Journal:  Stroke       Date:  2009-11-12       Impact factor: 7.914

4.  Intravenous thrombolytic therapy in patients with stroke mimics: baseline characteristics and safety profile.

Authors:  Y Chen; V Bogosavljevic; D Leys; D Jovanovic; L Beslac-Bumbasirevic; C Lucas
Journal:  Eur J Neurol       Date:  2011-03-02       Impact factor: 6.089

5.  How to identify stroke mimics in patients eligible for intravenous thrombolysis?

Authors:  A Förster; M Griebe; M E Wolf; K Szabo; M G Hennerici; R Kern
Journal:  J Neurol       Date:  2012-01-10       Impact factor: 4.849

6.  Efficacy of site-independent telemedicine in the STRokE DOC trial: a randomised, blinded, prospective study.

Authors:  Brett C Meyer; Rema Raman; Thomas Hemmen; Richard Obler; Justin A Zivin; Ramesh Rao; Ronald G Thomas; Patrick D Lyden
Journal:  Lancet Neurol       Date:  2008-09       Impact factor: 44.182

Review 7.  A review of the evidence for the use of telemedicine within stroke systems of care: a scientific statement from the American Heart Association/American Stroke Association.

Authors:  Lee H Schwamm; Robert G Holloway; Pierre Amarenco; Heinrich J Audebert; Tamilyn Bakas; Neale R Chumbler; Rene Handschu; Edward C Jauch; William A Knight; Steven R Levine; Marc Mayberg; Brett C Meyer; Philip M Meyers; Elaine Skalabrin; Lawrence R Wechsler
Journal:  Stroke       Date:  2009-05-07       Impact factor: 7.914

8.  Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study.

Authors:  Nils Wahlgren; Niaz Ahmed; Antoni Dávalos; Werner Hacke; Mónica Millán; Keith Muir; Risto O Roine; Danilo Toni; Kennedy R Lees
Journal:  Lancet       Date:  2008-09-12       Impact factor: 79.321

9.  Misdiagnosis of stroke in tissue plasminogen activator-treated patients: characteristics and outcomes.

Authors:  Phillip A Scott; Robert Silbergleit
Journal:  Ann Emerg Med       Date:  2003-11       Impact factor: 5.721

10.  Thrombolysis in stroke mimics: frequency, clinical characteristics, and outcome.

Authors:  David T Winkler; Felix Fluri; Peter Fuhr; Stephan G Wetzel; Philippe A Lyrer; Stephan Ruegg; Stefan T Engelter
Journal:  Stroke       Date:  2009-01-22       Impact factor: 7.914

View more
  2 in total

1.  Evaluation of telemedicine for new outpatient neurological consultations.

Authors:  Musa Mamman Watila; Callum Duncan; Graham Mackay
Journal:  BMJ Neurol Open       Date:  2022-05-06

2.  Telemedicine as the New Outpatient Clinic Gone Digital: Position Paper From the Pandemic Health System REsilience PROGRAM (REPROGRAM) International Consortium (Part 2).

Authors:  Sonu Bhaskar; Sian Bradley; Vijay Kumar Chattu; Anil Adisesh; Alma Nurtazina; Saltanat Kyrykbayeva; Sateesh Sakhamuri; Sebastian Moguilner; Shawna Pandya; Starr Schroeder; Maciej Banach; Daniel Ray
Journal:  Front Public Health       Date:  2020-09-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.